Search company, investor...
Myonexus Therapeutics company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Acquired | Acquired

Total Raised




About Myonexus Therapeutics

Myonexus Therapeutics is a clinical-stage gene therapy company developing corrective gene therapies for Limb-Girdle muscular dystrophies, debilitating rare diseases with no treatments.

Myonexus Therapeutics Headquarters Location

8000 Walton Parkway

New Albany, Ohio, 43054,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Myonexus Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Myonexus Therapeutics is included in 2 Expert Collections, including Biopharma Tech.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.


Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

Latest Myonexus Therapeutics News

Sarepta acquires Myonexus, reports LGMD trial results

Mar 4, 2019

Sarepta acquires Myonexus, reports LGMD trial results 12:08 PM PDF Sarepta Therapeutics Inc. (NASDAQ:SRPT) exercised its option to acquire Myonexus Therapeutics Inc. (New Albany, Ohio), giving it a pipeline of five gene therapy candidates to treat forms of limb-girdle muscular dystrophy (LGMD). Sarepta also revealed efficacy data from a Phase I/II trial of one of the candidates, MYO-101, in a cohort of patients with LGMD type 2E; the results exceeded expectations. Sarepta paid $165 million to exercise the buyout option, which it acquired in May 2018 for $60 million up front. Along with the type 2E candidate, Sarepta gains gene therapies to treat LGMD types 2D, 2B, 2C and 2L. Besides MYO-101, two programs have reached the clinic: MYO-102 for... Read the full 530 word article User Sign in

  • When was Myonexus Therapeutics founded?

    Myonexus Therapeutics was founded in 2017.

  • Where is Myonexus Therapeutics's headquarters?

    Myonexus Therapeutics's headquarters is located at 8000 Walton Parkway, New Albany.

  • What is Myonexus Therapeutics's latest funding round?

    Myonexus Therapeutics's latest funding round is Acquired.

  • How much did Myonexus Therapeutics raise?

    Myonexus Therapeutics raised a total of $2.5M.

  • Who are the investors of Myonexus Therapeutics?

    Investors of Myonexus Therapeutics include Sarepta Therapeutics, Rev1 Ventures, CincyTech, GFB Onlus and Jain Foundation.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.